文献速递血液透析通路

远端血运重建联合间期结扎治疗血管通路相关缺血的系统综述

A systematic review of distal revascularization and interval ligation for the treatment of vascular access-induced ischemia.
PubMed 文献 · J Vasc Surg · 2019-05-29

该系统综述纳入22项研究共459例接受DRIL的患者,缺血发生时间中位196天,3/4级缺血占52%,总体成功率为81%(95%CI 80.9%-82.5%),平均随访22.2个月,大隐静脉是最常用移植物(65%),聚四氟乙烯组移植物血栓发生率最高(43%)。结论认为DRIL长期结局良好,是治疗血管通路相关缺血的有效技术。

要点

  • DRIL治疗血管通路相关缺血的总体成功率为81%(95%CI 80.9%-82.5%)
  • 3/4级缺血是最常见表现(52%),缺血发生时间中位196天
  • 大隐静脉为最常用移植物(65%),聚四氟乙烯组血栓率最高(43%)

核心结论

  • DRIL具有足够的长期结局,是治疗血管通路相关缺血的有效技术。

研究设计与样本

  • 按PRISMA指南系统检索MEDLINE、CINAHL、Embase和Cochrane Library 1966至2017年文献。
  • 采用牛津CASP进行质量评价,并参照NICE评估实践推荐。
  • 共纳入22项研究、459例接受DRIL的患者,采用方差加权随机效应模型进行汇总。

主要发现

  • 缺血发生时间中位196天(四分位距30-600天)。
  • 3/4级缺血是最常见表现,占52%。
  • 总体成功率(1-4级)为81%(95%CI 80.9%-82.5%),平均随访22.2个月(四分位距1-60个月),中位随访18个月。
  • 首选移植物为大隐静脉(300/459,65%)。
  • 聚四氟乙烯组移植物血栓发生率最高(19/44,43%)。

临床怎么用

  • 对于血管通路相关缺血患者,DRIL可作为有效治疗选择,长期结局可接受。
  • 移植物选择上,大隐静脉使用最广泛,聚四氟乙烯组血栓风险较高需注意。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vascular access-induced ischemia remains a rare but significant complication of arteriovenous fistulas. Distal revascularization and interval ligation (DRIL) is one form of treatment. However, its collated efficacy through a systematic review is yet to be established. METHODS: An electronic and systematic search of the literature in MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Embase, and Cochrane Library from 1966 to 2017 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was conducted. Quality assessment of the articles was performed using the Oxford Critical Appraisal Skills Programme, and the recommendation for practice was examined through the National Institute for Health and Care Excellence. Data of treated cases, success, time to ischemia, follow-up, age, sex, diabetes mellitus, fistula type, conduit type, and grade of ischemia were extracted and subjected to a pooled variance-weighted random-effects model. RESULTS: Twenty-two studies (n = 459 individuals) were subjected to DRIL. Time to ischemia was 196 days (interquartile range, 30-600 days). Ischemia grade 3/4 (52%) was the most common presentation. The overall success (grades 1-4) was 81% (95% confidence interval, 80.9%-82.5%) during a mean and median follow-up of 22.2 months (interquartile range, 1-60 months) and 18 months, respectively. The conduit of choice was the great saphenous vein (n = 300/459 [65%]), and bypass thrombosis was highest in the polytetrafluoroethylene group (n = 19/44 [43%]). CONCLUSIONS: DRIL with adequate long-term outcomes is an effective technique for the treatment of vascular access-induced ischemia.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kordzadeh A, Parsa AD. A systematic review of distal revascularization and interval ligation for the treatment of vascular access-induced ischemia. J Vasc Surg. 2019. PMID: 31153703. doi:10.1016/j.jvs.2019.02.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。